Tyzzerella

Tyzzerella is a gut bacterium that rises and falls with what you eat. In one study of 34 adults, people eating more saturated fat and more trans fat carried more of it in the colon, and the link held up after accounting for other differences between those people.

That makes it a dietary readout more than a diagnosis. Treat this result as a research-grade signal about the direction your gut ecology is heading, not as a test that tells you whether you have a disease.

What This Test Actually Measures

Tyzzerella is a genus of oxygen-avoiding bacteria in the Lachnospiraceae family. It lives in both the gut lining and the gut contents, so a stool sample picks it up. The lab finds it by copying specific stretches of bacterial DNA over and over until there is enough to count, a method called PCR. The strongest diet evidence, though, comes from tissue scraped off the colon wall rather than from stool, and the two sample types do not always agree, so read that link as directional. Broader human studies of saturated fat and this family of bacteria have gone in both directions, so this is one thread rather than a settled finding.

The test counts bacterial genes, not living bugs. DNA from an organism that is barely active, or that passed through recently, amplifies the same way as DNA from a thriving population. That limit applies to every molecular stool assay and is the reason a single number here means less than the direction it moves.

The labels need explaining. Sequencing databases split this genus into subgroups, usually written Tyzzerella 3 and Tyzzerella 4. Most of the metabolic findings below come from Tyzzerella 4. One cardiac finding comes from Tyzzerella 3, and it points the opposite way. Which subgroup a study measured changes what the result means.

Blood Sugar in Pregnancy

One human finding involves early pregnancy. In a study of nearly 200 pregnant women sampled between 10 and 15 weeks, women who later developed gestational diabetes were already carrying more Tyzzerella 4 in the first trimester than women whose blood sugar stayed normal. Within that group, higher levels tracked with higher fasting blood sugar.

The same researchers built a prediction model using several gut genera, including this one. When they tested it on a separate group of women, it landed at an area under the curve of 0.696. That number runs from 0.5, which is a coin flip, to 1.0, which is perfect. So the model did better than chance and nowhere near well enough to replace an oral glucose tolerance test.

That result comes from one cohort and has not been reproduced. A systematic review pooling 21 studies of the gut microbiome in gestational diabetes found no consistent set of bacteria associated with the condition. Genera moved in opposite directions from study to study, only Collinsella and Blautia trended the same way across cohorts, and the first-trimester studies specifically did not agree with each other. This genus was not among the consistent ones.

So a high reading here is not a reason to change anything about your pregnancy care. Nobody has shown this genus predicts gestational diabetes well enough to act on. If you want an earlier read on blood sugar, fasting glucose and fasting insulin answer that question directly, and the standard glucose tolerance screen remains the test that establishes the diagnosis.

Colorectal Adenomas

In a screening study of 1,546 adults aged 50 to 74, Tyzzerella 4 was more abundant in people found to have advanced colorectal adenomas. Those are the precancerous growths colonoscopy is looking for. On its own the genus was close to useless for telling those people apart, with an adjusted area under the curve of 0.545, barely above a coin flip.

Bundled with twelve other bacteria and added to the fecal immunochemical test, the combination caught 41.1% of advanced adenomas while correctly clearing 80 out of 100 people without them. Add age, sex, smoking, and family history on top and the combined model reached an adjusted area under the curve of 0.706.

None of that changes your colonoscopy schedule. No trial has shown that finding this bacterium catches a cancer earlier or improves any outcome. Colonoscopy and the fecal immunochemical test remain the screening that has actually been shown to work. Get them on schedule whatever your microbiome panel says.

Where the Evidence Points Both Directions

Most of what you have read so far says higher is worse. One study says the opposite. In a comparison of 30 people admitted with an acute heart attack and 30 healthy controls, the heart attack group carried markedly less Tyzzerella 3, alongside lower overall bacterial diversity and shifts in the short-chain fatty acid pathways gut bacteria use to make fuel for the colon lining.

These two findings only look contradictory if you think of this as a good-number-bad-number marker. It isn't. What matters is the pattern the whole community is in, not whether one genus is up or down. Different subgroups of the genus behave differently, and being acutely ill reshapes the whole gut community in ways that have nothing to do with what caused the illness. Read this alongside your other markers, never alone.

Other Conditions Where It Appears

Several smaller studies have found this genus enriched in people who already have a diagnosis. Women with polycystic ovary syndrome and obesity carried more of it, and its levels moved with their androgen and steroid hormone profiles. Elderly people with liver cancer and cirrhosis carried more of it, alongside other inflammation-driving and alcohol-producing bacteria. It has also come up as elevated in people with active Crohn's disease.

Each of those is a single study, and where larger pooled analyses exist, this genus does not survive them. Reviews that combine the polycystic ovary syndrome microbiome studies list a different set of bacteria as consistently altered, and this one is not on it. That pattern, a result that appears once and does not replicate, is common in microbiome research.

Every one of those studies also looked at people at a single point in time, after they were already sick. None of them can tell you whether the bacterium contributed to the disease, responded to it, or simply traveled with the diet and medications that came with it. Nobody has run a trial that changes this genus on purpose and then measures what happens to the person.

Why One Reading Is Not Enough

Gut bacteria move. A week of travel, a course of antibiotics, a stretch of eating differently, a bout of illness: all of them reshape the community, sometimes for weeks. Antibiotic studies in healthy adults show diversity dropping fast and most people recovering over weeks to months, with some drifting for much longer. Nobody has measured how much this particular genus swings within one person over time, which is itself a reason to distrust any single reading.

There are no validated reference ranges here. The high or low label on your report is a percentile against whatever population that lab happens to have sampled, not a clinical threshold anyone has validated against an outcome. Your own baseline is the only comparison that means much.

So get a baseline. If you change your diet, retest a few months later and see whether the number moved with the change. The value is in the trajectory and in whether your interventions do anything, not in where you land on someone else's curve today.

When Results Can Be Misleading

Recent antibiotics matter more than anything else here. Commonly prescribed antibiotics cut gut diversity sharply and the community usually takes weeks to drift back toward baseline, with some people not fully recovering for months. A sample taken during or soon after a course tells you about the antibiotic, not about your usual gut.

• Recent antibiotics: wait at least four to six weeks after finishing a course before sampling, and longer if you can.
• Acute illness: being sick reshapes the whole community. The heart attack study is a reminder that an acute event shifts the gut in ways unrelated to what you want to measure.
• A short-term diet change: a week of eating unusually before the sample skews the result toward that week, not toward your usual pattern. Sample during a normal stretch.
• DNA is not a headcount: PCR amplifies genetic material whether the organism is thriving, barely present, or passing through. A number cannot tell you which.

What to Do With an Out-of-Pattern Result

Think in combinations, not in this one number. If this genus reads high and you also see elevated fasting insulin, a rising HbA1c, or triglycerides climbing, you are looking at a metabolic picture, and the metabolic markers are the ones to act on and track. Order fasting insulin and glucose together, not glucose alone, since insulin moves first. None of those next steps are driven by the bacterial number itself. They are worth doing because those markers carry information, and this one does not yet.

If it reads high alongside digestive symptoms, the useful next test is fecal calprotectin. It separates real inflammation in the gut lining from a functional problem, and that distinction changes what you do next. Bring in a gastroenterologist if calprotectin comes back elevated, if you have blood in your stool, or if symptoms have run more than a few weeks.

If it reads high and everything else looks clean, change nothing dramatic, retest in a few months, and watch whether it holds. An isolated shift in one bacterial genus, with no symptoms and no supporting labs, is not a finding that justifies treatment. Nobody has shown that treating this number helps anyone.